No Evidence for Recent Abacavir/Lamivudine Use in Promoting Inflammation, Endothelial Dysfunction, Hypercoagulability, or Insulin Resistance in Virologically Suppressed HIV-infected patients: A Sub-study of the BICOMBO Randomized Clinical Trial E. Martínez , M. Larrousse, I. Pérez, M. Loncá, D. Podzamczer, F. Gutiérrez, R. Deulofeu, R. Casamitjana, J.C. Reverter, J. Mallolas, J. Pich, J.M. Gatell, for the BICOMBO Study Group
15
Embed
No Evidence for Recent Abacavir/Lamivudine Use in Promoting Inflammation, Endothelial Dysfunction, Hypercoagulability, or Insulin Resistance in Virologically.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
No Evidence for
Recent Abacavir/Lamivudine Use in Promoting
Inflammation, Endothelial Dysfunction,
Hypercoagulability, or Insulin Resistance in
Virologically Suppressed HIV-infected patients:
A Sub-study of the
BICOMBO Randomized Clinical Trial
E. Martínez, M. Larrousse, I. Pérez, M. Loncá,
D. Podzamczer, F. Gutiérrez, R. Deulofeu, R. Casamitjana,
J.C. Reverter, J. Mallolas, J. Pich, J.M. Gatell,
for the BICOMBO Study Group
SPAIN
ABACAVIR AND CV DISEASE• Abacavir use identified as a marker of cardiovascular disease in
several cohort studies (1-3), although it is currently unclear whether its role is causative or not.
• Potential pathogenetic mechanisms are also unclear. Abacavir has not been asociated with insulin resistance (4) or lipoatrophy (4, 5) and its lipid impact is lower than that of stavudine (5) or protease inhibitors (6), although higher than that of tenofovir (7).
• Several potential mechanisms affecting biological mechanisms associated with cardiovascular dysfunction have been suggested (6-8) but studies to date may have been subjected to bias.1. D:A:D Study Group. Lancet 2008; 371: 1417-1426
2. The SMART/INSIGHT and the D:A:D Study Groups. AIDS 2008; 22: F17-F243. Obel N, et al. HIV Medicine 2009 (Epub ahead of print)4. Shlay JC, et al. JAIDS 2005; 38: 147-1555. Podzamczer D, et al. J Acquir Immune Defic Syndr. 2007; 44: 139-1476. Martinez E, et al. N Engl J Med 2003; 349: 1036-10467. Smith KY, et al. AIDS 2009; 23: 1547-15566. Hsue PY, et al. AIDS. 2009; 23: 2021-20277. Satchell C, et al. 16th CROI, 2009. Montreal, Canada. Abstract 151LB8. Kristoffersen US, et al. HIV Medicine 2009 (Epub ahead of print)
J Lundgren & DAD Study Group et al CROI 2009 LB abstr 44
D:A:D STUDY: ABC, TDF, and MYOCARDIAL INFARCTION
Recentuse
Cumm.use
Initiation Progression Complication
InflammationEndothelial dysfunction
Insulin resistance
Hypercoagulability
ABC
TDF
MECHANISMS FOR MYOCARDIAL INFARCTION
1. D:A:D Study Group. Lancet 2008. 2. The SMART/INSIGHT and the D:A:D Study Groups. AIDS 2008.3. D:A:D Study Group. CROI 2009.
3
1-3
POTENTIAL SOURCES OF CONFOUNDING AND BIAS
• Drug prescription not random
• Pre-existing CV disease or DM
• Uncontrolled HIV infection or AIDS
Patients randomized (n=335)PI=34
NNRTI=301
Stable 3TC-based ART for > 6 months
HIV-RNA < 200c/mL
No HLA screening
ABC/3TC (n=167) TDF/FTC (n=168)
Excluded (n=2)Excluded (n=0)
ABC/3TC (n=167) TDF/FTC (n=166)
Discontinue ABC/3TC(n=30, 18%)
Discontinue TDF/FTC (n=22, 13%)
Continue on ABC/3TC(n=137, 82%) *
Continue on TDF/FTC(n=144, 87%)
Primary Analysis, Week 48
BICOMBO STUDY DESIGN
Martinez E et al. J Acquir Immune Defic Syndr 2009.
* 1 patient with virological failure and 1 with a new AIDS event
METHODS• Patients
– Baseline and 48w serum samples available– No history of symptomatic CV disease or DM– No virological failure or AIDS events during follow-up
• Laboratory markers
• Statistical analyses– Wilcoxon rank Sum test for comparisons– Punctual estimation and 95% confidence interval of difference in medians (methodology of
Hodges-Lehman, using the distribution-free of Moses). – Spearman test for correlations
Initiation Progression Complication
InflammationEndothelial dysfunction
Insulin resistance
Hypercoagulability
hsCRP, MCP-1OPG, IL-6TNF-alpha
IL-10ICAM-1, VCAM-1
Selectin E, Selectin PAdiponectin, Insulin
D-dimer
POPULATION CHARACTERISTICS
P>0.05 for all comparisons between groups (ABC/3TC vs TDF/FTC) in the Sub-study.P>0.05 for all comparisons between patients in the Sub-study vs patients from the BICOMBO study not in the Sub-study.
BICOMBO Sub-study BICOMBO Study
ABC/3TC
(n=46)
TDF/FTC
(n=34)
Patients in the Sub-study
(n=80)
Patients not in the Sub-study
(n=253)
Age (years) 44 (39-52) 42 (37-49) 43 (38-48) 43 (38-48)
• Because hsCRP is the marker with more widespread clinical use, we performed additional analyses.
• Absolute hsCRP increase at 48 weeks: 18(39%) and 11 (32%) patients in the ABC/3TC and TDF/FTC groups respectively (P=0.62).
• hsCRP higher than 0.5 mg/dL at 48 weeks: 4(9%) and 1 (3%) patients in the ABC/3TC and TDF/FTC groups respectively (P=0.39).
• hsCRP increase at 48 weeks 25% higher than that at the baseline: 16(35%) and 9 (26%) patients in the ABC/3TC and TDF/FTC groups respectively (P=0.61).
CONCLUSIONS• In otherwise healthy, virologically suppressed HIV-
infected patients from the BICOMBO study, the initiation of ABC/3TC did not lead to significant changes after 48 weeks in markers of inflammation, endothelial dysfuntion, insulin resistance, or hypercoagulability as compared with the initiation of TDF/FTC.
• These results argue against any of these mechanisms as involved in the higher risk of MI associated with recent ABC use in some cohort studies.
ACKNOWLEDGEMENTS• Supported in part by research grants from Gilead Sciences and GlaxoSmithKline
• Participating centers and investigators (in alphabetical order):Hospital de Bellvitge, L’Hospitalet (Patricia Barragán, Elena Ferrer, Daniel Iñiguez, Gabriela Leibenger, Daniel Podzamczer)
Hospital Clínic, Barcelona (Mireia Arnedo, José L Blanco, Marta Calvo, José M Gatell, Montserrat Laguno, María Larrouse, Agathe León, Montserrat Loncá, Josep Mallolas, Esteban Martínez, María Martínez, Ana Milinkovic, José M. Miró, Tomás Pumarola)
Hospital Clínico de San Carlos, Madrid (Mónica Fuster, Victor Roca†)
Hospital General Universitario de Elche, Elche (Enrique Bernal, Félix Gutiérrez, Mar Masiá, Sergio Padilla).